Health – Fish Vet Group
Licensed against
TRUSTED sea lice treatment has under- gone improvements that make it more effective and also reduce the chance of resistance occurring, claim its manu-
lice A
facturers. Fish Vet Group’s new formulation of Sal- mosan will provide customers with more flexi- bility of use while retaining all the efficacious and safety properties of the original, says the company. The new version is named Salmosan Vet and
is available now. Technical director John Marshall said the
changes in the product are part of an ongoing investment into sea lice management and will ensure customers have greater confidence in compliance with EU residue guidelines. ‘Commission Regulation No 37/2010
instructs that excipients without an MRL and not excluded from needing an MRL in medicines should be removed. We have done so with Salmosan Vet and our product is the only azamethiphos based sea lice product in Europe that complies. ‘We have a full marketing authorisations
granted by the Norwegian Medicines Agency in Norway and the VMD in the UK.’ As part of the licensing process, Marshall
explains that the teams at Fish Vet Group and sister company Benchmark Animal Health took the opportunity to expand the support- ing trial work. ‘We wanted to further improve the practi-
cality of using Salmosan Vet. Our intensive trial work demonstrated that Salmosan Vet
36
Right: Salmosan Vet is available now
can be used for a full one-hour treatment at water temperatures up to 15 deg C, so this indication is now included on the label. ‘To achieve this the product underwent strict safety trials that
consisted of treating fish for extended periods of time and at higher dose rates. Being able to treat for up to an hour at 15 deg C without deviation from the data sheet should really make a difference to our customers. ‘We believe that enabling lengthier treatment times will lead to
more effective sea lice treatments and reduce the chance of resist- ance occurring.’ Fish Vet Group have also ensured that the dispersal and efficacy of
the product remained as good as original Salmosan. ‘Identical Salmosan Vet and Salmosan treatments were carried out
and the azamethiphos concentration measured at three different locations over the course of a 60-minute treatment,’ said Marshall. ‘We were pleased to see that dispersal rates were the same. ‘All our trial work has demonstrated that the new formulation meets
the high standards set by original Salmosan. We are confident that fish farmers and their health advisers can make the move over to the improved product and expect the same efficacy.’ The original formulation of Salmosan will remain on the market in
www.fishfarmer-magazine.com
Improved formulation gives fish farmers even more flexibility
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68